Business Context and Reporting Period
Meiwu Technology Company Limited filed this Form 6-K for September 2026 as a foreign private issuer filing annual reports on Form 20-F. The report is dated September 23, 2026 and describes the completion of an acquisition by its indirectly wholly owned subsidiary, Xiamen Chunshang Health Technology Co., Ltd.
Transaction and Key Financial Information
- On September 22, 2026, Xiamen Chunshang completed the acquisition of 100% of Xiamen Hemeitong Commercial Co., Ltd. from its two shareholders.
- The transaction was conducted under an equity transfer agreement dated August 20, 2026.
- Cash consideration totaled RMB235.2 million, approximately US$35.0 million.
- Xiamen Hemeitong became a wholly owned subsidiary of Xiamen Chunshang and, indirectly, of Meiwu Technology.
- The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, purchase-price allocation, or pro forma financial information related to the acquisition.
Changes Versus the Prior Comparable Period
The filing does not provide comparative financial statements or period-over-period operating results. The principal reported change is the addition of Xiamen Hemeitong as a wholly owned subsidiary following the September 22, 2026 closing.
Outlook, Risks, and Unusual Items
- Management states that forward-looking statements may relate to strategic plans, potential acquisitions, realization of transaction benefits, industry and competitive developments, future revenue and expenses, capital requirements, and financing needs.
- The acquisition consideration represents a material cash outflow; the filing does not explain the funding source or its impact on liquidity.
- Identified risks include the ability to execute strategic plans, consummate attractive acquisitions, realize anticipated benefits, respond to competition and industry developments, and obtain additional financing if needed.
- Actual results may differ materially from expectations because of known and unknown risks, uncertainties, and assumptions. The company does not undertake to update forward-looking statements except as required by law.
Important Facts for Investors to Verify
- Review the acquisition agreement and any exhibits for closing conditions, representations, indemnities, and other transaction terms.
- Verify the source of the RMB235.2 million cash consideration and assess the resulting effect on cash, debt, and liquidity.
- Obtain financial information for Xiamen Hemeitong, including revenue, profitability, assets, liabilities, and cash flow.
- Assess purchase accounting, goodwill or other intangible assets, and any required SEC disclosures.
- Monitor whether management provides guidance regarding the acquired business, expected synergies, integration costs, or future financing needs.